Heparanase activity and bone loss in postmenopausal breast cancer patients

被引:2
作者
Altundag, K [1 ]
Altundag, O
Baptista, MZ
Akyurek, S
机构
[1] Univ Hacettepe, Inst Oncol, Dept Med Oncol, TR-06100 Ankara, Turkey
[2] Hosp Maternidade Campinas, Dept Clin Oncol, Campinas, SP, Brazil
[3] Ankara Univ, Sch Med, Dept Radiat Oncol, TR-06100 Ankara, Turkey
关键词
D O I
10.1200/JCO.2005.04.0121
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:8916 / 8917
页数:2
相关论文
共 2 条
[1]   Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases [J].
Kelly, T ;
Suva, LJ ;
Huang, Y ;
MacLeod, V ;
Miao, HQ ;
Walker, RC ;
Sanderson, RD .
CANCER RESEARCH, 2005, 65 (13) :5778-5784
[2]   Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer [J].
Lonning, PE ;
Geisler, J ;
Krag, LE ;
Erikstein, B ;
Bremnes, Y ;
Hagen, AI ;
Schlichting, E ;
Lien, E ;
Ofjord, ES ;
Paolini, J ;
Polli, A ;
Massimini, G .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5126-5137